In The Know: How do US oncologists rate NSCLC therapies?

Where do the brand loyalties lie among US oncologists in the treatment of non-small cell lung cancer (NSCLC)?  When asked to rate treatment options, a sample of 100 US physicians gave Keytruda the highest ranking, 17 points higher than second place Opdivo, in terms of overall brand satisfaction. (See Table 1).

Table 1: NSCLC therapies ranked by US oncologists for brand satisfaction

Source: FirstWord NPS+ (US) -- Non-small Cell Lung Cancer (NSCLC) (2017)

Based on the Net Promoter Score (NPS) system, of the 12 brands featured in the 2017 survey, seven received positive scores. The results show that brand health varies across the available therapies, with a gap of 99 ranking points between the brands in first and last place.

Responses to the 2018 survey will be available in the coming weeks, and will show how NSCLC brand loyalties have shifted over the past 12 months (click here to be notified when results are available). See Table 2 for the brands that feature in the survey.
 

Table 2: Brands included in the upcoming NSCLC 2018 survey


FirstWord has conducted similar research in 14 competitive disease areas across the US and EU. Contact us to learn more.

To read more Sponsored Story articles, click here.

Reference Articles